Peter Lichtlen
Director/Board Member at LYSOGENE
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Karen Pignet-Aiach | F | 52 | 15 years | |
| David Urech | M | - |
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | 13 years |
| Oliver Middendorp | M | - |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | 13 years |
| Côme de La Tour du Pin | M | - | 4 years | |
| Michel Picot | M | 72 | - | |
| Marie Deneux | M | - | - | |
| Carole Deffez | F | - | 5 years | |
| Céline Fantin | F | - | - | |
| Zhen Ping Zhu | M | 59 |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | 6 years |
| Carlo Incerti | M | 65 |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | 3 years |
| Nanna Liebach Lüneborg | M | 49 |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | 3 years |
| Yves Nordmann | M | - |
FMH Swiss Medical Association
 FMH Swiss Medical Association Miscellaneous Commercial ServicesCommercial Services FMH Swiss Medical Association operates an association for doctors and medical practitioners. The private company is based in Bern, Switzerland and has subsidiaries in Switzerland. | - |
| Andreas Plückthun | M | 65 |
University of Zurich
| 31 years |
| Ralph Laufer | M | - | 6 years | |
| Mark G. Egan | M | - |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | - |
| Hans Wehrli | M | 71 |
University of Zurich
| 31 years |
| Marie Trad | M | - | 2 years | |
| Ignacio Melero | M | - |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | - |
| Daniel Vasella | M | 70 |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Annette Clancy | F | 70 | 5 years | |
| Ryuji Ueno | M | 70 |
Sucampo GmbH
 Sucampo GmbH Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Sucampo GmbH is a Swiss company that manufactures and distributes pharmaceuticals and health care products. The company is based in Zug, Switzerland. The company was founded by Ryuji Ueno, Sachiko Kuno. Sucampo was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on December 29, 2010 for $120 million. | 17 years |
| Rolf M. Zinkernagel | M | 80 |
University of Zurich
| 16 years |
| Philippe Pierre Goupit | M | - | - | |
| Judith Bischof | M | 50 |
University of Zurich
| 6 years |
| Iris Bohnet Zürcher | M | 58 |
University of Zurich
| 5 years |
| Thomas Meier | M | - |
University of Zurich
| 6 years |
| Olivier Danos | M | 66 | 9 years | |
| Michael Sidler | M | 55 |
University of Zurich
| 8 years |
| David S. Schilansky | M | 48 | 6 years | |
| Thomas Roland Meier | M | 61 |
University of Zurich
| 4 years |
| Philippe Weber | M | 59 |
University of Zurich
| 5 years |
| Rene Dittrich | M | 52 |
University of Zurich
| 6 years |
| Kimberley S. Gannon | M | - | - | |
| Wolfgang Weber | M | 57 |
University of Zurich
| 3 years |
| Anne-Marie M. Solari Bozzi-Altenburg | F | 56 |
University of Zurich
| 3 years |
| Daniel Anders | M | 54 |
University of Zurich
| 4 years |
| Silvio Inderbitzin | M | 59 |
University of Zurich
| 4 years |
| Horst Rzepka | M | 57 |
University of Zurich
| 2 years |
| Marco Probst | M | - |
University of Zurich
| 5 years |
| Stéphane Durant des Aulnois | M | - | 4 years | |
| Adrian Widmer | M | 56 |
University of Zurich
| 6 years |
| Marcel Huber | M | - |
University of Zurich
| 6 years |
| Gabrielle Nater-Bass | F | 56 |
University of Zurich
| 3 years |
| Martin Eisenring | M | - |
University of Zurich
| 3 years |
| Andreas Knecht | M | 55 |
University of Zurich
| 6 years |
| Oliver Hofmann | M | 53 |
University of Zurich
| 4 years |
| Nic Dreckmann | M | 50 |
University of Zurich
| 4 years |
| Werner Lüscher | M | - |
University of Zurich
| 2 years |
| Ruedi Noser | M | 63 |
University of Zurich
| 4 years |
| André Odermatt | M | 64 |
University of Zurich
| 4 years |
| Daniel von Stockar | M | - |
University of Zurich
| 3 years |
| Hans Wicki | M | 60 |
University of Zurich
| 5 years |
| Rudolf Marty | M | 75 |
University of Zurich
| 10 years |
| Dimitri Papadopoulos | M | - |
University of Zurich
| 3 years |
| Thomas Gottstein | M | 60 |
University of Zurich
| 3 years |
| Reto Schnabel | M | - |
University of Zurich
| 4 years |
| David Enrico Tizzoni | M | 59 |
University of Zurich
| 7 years |
| Sean O'Bryan | M | - | 2 years | |
| Morten Holm Pedersen | M | - |
University of Zurich
| 2 years |
| Philippe Mendels-Flandre | M | - | 1 years | |
| Teodoro D. Cocca | M | 51 |
University of Zurich
| 4 years |
| Karl Stefan Mäder | M | 61 |
University of Zurich
| 3 years |
| Peter Steiner | M | - |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 13 years |
| Markus Foser | M | 55 |
University of Zurich
| 4 years |
| Christian Hasler | M | - |
University of Zurich
| 5 years |
| Haleh Brönner | M | 55 |
University of Zurich
| 6 years |
| Rahul Sen Gupta | M | 52 |
University of Zurich
| 1 years |
| Mathias Schmid | M | 60 |
University of Zurich
| 3 years |
| Patrik Forrer | M | - |
University of Zurich
| 3 years |
| Peter-Mark Vogel | M | 58 |
University of Zurich
| 4 years |
| Beat Buehlmann | M | 56 |
University of Zurich
| 3 years |
| Philippe Schenk | M | - |
University of Zurich
| 3 years |
| Sven Zimmermann | M | 53 |
University of Zurich
| 3 years |
| Urs Wälchli | M | 57 |
University of Zurich
| 1 years |
| Chris Burger | M | - |
University of Zurich
| 6 years |
| Michael Altorfer | M | - |
University of Zurich
| 3 years |
| Christian C. Wenger | M | 60 |
University of Zurich
| 3 years |
| Nicole Tschudi | F | 52 |
University of Zurich
| 5 years |
| Thomas O. Hecht | M | 73 |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | 5 years |
| Giacomo Balzarini | M | 56 |
University of Zurich
| 4 years |
| Reto Suter | M | 53 |
University of Zurich
| 5 years |
| Anne Schmidt | M | - |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | - |
| Marc Loeb | M | 53 |
University of Zurich
| 1 years |
| Nicola C. Port | F | - |
University of Zurich
| 3 years |
| Patrick Schildknecht | M | 52 |
University of Zurich
| 4 years |
| Johannes Suter | M | - |
University of Zurich
| 5 years |
| Christian Wiesendanger | M | 60 |
University of Zurich
| 4 years |
| Elisa Parisi-Capone | F | - |
University of Zurich
| 6 years |
| Silvano Maffeis | M | 57 |
University of Zurich
| 3 years |
| Martin Paul Zehnder | M | 56 |
University of Zurich
| 3 years |
| Thomas Oetterli | M | 55 |
University of Zurich
| 4 years |
| Da Blumer | M | 56 |
University of Zurich
| 4 years |
| Beat Walti | M | 55 |
University of Zurich
| 3 years |
| Andreas Schulthess | M | 54 |
University of Zurich
| 4 years |
| Roger Meier-Rossi | M | - |
University of Zurich
| 3 years |
| Alexander Gut | M | 61 |
University of Zurich
| 3 years |
| Patrick Rene Stutz | M | - |
University of Zurich
| 6 years |
| Thomas Moser | M | 57 |
University of Zurich
| 3 years |
| Daniel Schmucki | M | 56 |
University of Zurich
| 4 years |
| Marc Weber | M | 53 |
University of Zurich
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 84 | 84.00% |
| France | 16 | 16.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter Lichtlen
- Personal Network
